TRASTUZUMAB-QYYP | B761081 | PFIZER INC
Earliest legal licensure (12-year BPCIA floor)
The 12-year reference-product exclusivity is the non-carveable floor — the earliest FDA could license a biosimilar for any indication. Unverified estimate — derived from the earliest available approval record (Mar. 11, 2019), not an FDA-stated exclusivity date. Shown with lower confidence than a Purple Book value.
Full-label vs. best-skinny biosimilar entry
| Scenario | Date | Status | Controlling |
|---|---|---|---|
| Best-skinny entry (floor) | Mar. 11, 2031 | 4y 7mo remaining | 12-year RPE floor (non-carveable) |
| Full-label entry | Mar. 11, 2031 | 4y 7mo remaining | 12-year RPE floor |
Best-skinny equals full-label — no carveable orphan block runs past the licensure floor.
Marketing-entry ceiling (litigation risk)
Patents do not gate FDA licensure of a biosimilar — FDA licenses biosimilars (full or carved label) without adjudicating any patent. These are a practical marketing-entry ceiling resolved in the § 262(l) patent dance and ordinary litigation. A formulation/compound patent caps practical skinny entry via litigation (Regeneron v. Mylan); a method-of-use patent is carveable and gates nothing.
Latest formulation/compound patent 11980669· AI-discovered, not Purple-Book-listed · relevance 85/100. This caps practical skinny-label entry; it does not move the licensure floor above.
32 formulation/compound (cap skinny entry) · 3 method-of-use (carveable — gate nothing) · 15 device/diagnostic/manufacturing
| Patent | Class | Expiration | Source |
|---|---|---|---|
| 11980669 | Formulation/compound | May. 9, 2044Active | Discovered |
| 11944689 | Formulation/compound | Mar. 28, 2044Active | Discovered |
| 11712480 | Formulation/compound | Jul. 27, 2043Active | Discovered |
| 11674240 | Formulation/compound | Jun. 8, 2043Active | Discovered |
| 11661438 | Formulation/compound | May. 25, 2043Active | Discovered |
| 11578428 | Formulation/compound | Feb. 9, 2043Active | Discovered |
| 11319526 | Formulation/compound | Apr. 28, 2042Active | Discovered |
| 11173196 | Formulation/compound | Nov. 11, 2041Active | Discovered |
| 11053321 | Method-of-use (carveable) | Jul. 1, 2041Active | Discovered |
| 10941216 | Formulation/compound | Mar. 4, 2041Active | Discovered |
| 10870706 | Formulation/compound | Dec. 17, 2040Active | Discovered |
| 10775381 | Other | Sep. 10, 2040Active | Discovered |
| 10653794 | Formulation/compound | May. 14, 2040Active | Discovered |
| 10647756 | Formulation/compound | May. 7, 2040Active | Discovered |
| 10570189 | Formulation/compound | Feb. 20, 2040Active | Discovered |
Showing 15 of 50 patents (latest expirations).
Approved Biosimilars
Disclaimer: Identifying an available carve-out is not a prediction that FDA will approve the particular carved label, nor that marketing it is free of infringement risk. For biologics, availability turns on exclusivities, not patents: FDA licenses a biosimilar (full or carved label) without adjudicating any patent, and patent disputes run through the § 262(l) patent dance and ordinary litigation, outside this availability view.
Top 50 of 66 AI-discovered patents by relevance.
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
| D. Del. | 2017-11-17 | Terminated 2018-12-04 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
No patent or exclusivity listings for this strength.